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Abstract
To improve cancer immunotherapy, a better understanding of the weak efficiency of tumor-infiltrating T lymphocytes (TIL)
is necessary. We have analyzed the functional state of human TIL immediately after resection of three types of tumors
(NSCLC, melanoma and RCC). Several signalling pathways (calcium, phosphorylation of ERK and Akt) and cytokine secretion
are affected to different extents in TIL, and show a partial spontaneous recovery within a few hours in culture. The global
result is an anergy that is quite distinct from clonal anergy induced in vitro, and closer to adaptive tolerance in mice. PD-1
(programmed death -1) is systematically expressed by TIL and may contribute to their anergy by its mere expression, and
not only when it interacts with its ligands PD-L1 or PD-L2, which are not expressed by every tumor. Indeed, the TCR-induced
calcium and ERK responses were reduced in peripheral blood T cells transfected with PD-1. Inhibition by sodium
stibogluconate of the SHP-1 and SHP-2 phosphatases that associate with several inhibitory receptors including PD-1,
relieves part of the anergy apparent in TIL or in PD-1-transfected T cells. This work highlights some of the molecular
modifications contributing to functional defects of human TIL.
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Introduction
One of the generally accepted reasons for which the immune
system has a low efficacy for fighting cancers is that tumor-
infiltrating lymphocytes (TIL) are dysfunctional, because of an
immmunosuppressive tumor microenvironment, and because TIL
express inhibitory receptors, like PD-1. PD-1 is a receptor
expressed by cells that are chronically activated, for instance in
chronic viral diseases such as HIV, and it appears to contribute to
the exhausted state of these cells [1]. Although these general
notions are widely accepted, a closer look shows that the functional
state of TIL remains ill-defined and would deserve a more
stringent examination.
First, it is generally assumed that the functional state of TIL,
corresponds to an alteration of early TCR signalling, as some key
kinases (Lck, ZAP-70) have been described to be affected in such
murine cells [2]. Some reports have mentioned the reduced
expression of CD3f in T cells from cancer patients [3,4].
However, this latter explanation cannot be a general one, as in
several cancers including lung, CD3f expression was found to be
normal [5,6,7]. The potential link between dysfunctions in early
TCR signalling and expression of inhibitory receptor like PD-1 has
not been addressed in fresh human TIL. Which are the early
signalling pathways, such as calcium (Ca), ERK, Akt, that are
affected in TIL, and to what extent inhibitory receptors are
involved? In addition, in a number of studies, the functional state
of TIL has been assessed after stimulating the cells with a
combination of PMA and ionomycin. Such stimulation is
informative on the differentiation state of the cells. However, it
is inappropriate for evaluating the existence of alterations in early
TCR signalling. For instance, both naı ¨ve and memory T cells
show good responses in terms of early signalling with Ca or ERK
as readouts; however, only effector/memory cells are able to
secrete IFN-c after stimulation by PMA/ionomycin, thus revealing
their distinct differentiation state. Surprisingly, although several
papers have shown that TIL are experienced T cells, as judged by
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[8,9], others have described a failure to respond to these stimuli
[10,11].
A second problem relates to the T cell types that must be
evaluated and compared, to understand T cell dysfunction in
cancer. Although at late stages of the disease, a general defect of
the immune system may be observed [4], at earlier stages, the
function of anti-tumor specific T cells found in peripheral blood
seems practically normal, and only TIL behaving abnormally [12].
It thus appears important to concentrate first on the analysis of
defects observed in T cells found in the tumor microenvironment.
But to which cells should TIL be compared? Peripheral blood T
cells (PBT) constitute a first possible reference. If one wishes to
compare TIL to T cells found in tissues, one should distinguish
lymph nodes, visited by naı ¨ve and central memory T cells, and
inflamed tissues, infiltrated by activated and memory T cells. In
lymph nodes, the presence of chemokines [13], cytokines, and
weak stimulation by self peptides on dendritic cells [14] results in a
hypersensitivity of these cells to TCR stimulation, compared to the
sensitivity of PBT. On the contrary, in inflamed tissues,the
presence of a number of factors such as TGF-b results in an
alteration of the sensitivity of these cells to TCR stimulation,
compared to that of PBT [12]. In tumors, one expects to find a
combination of immunosuppressive factors that are shared with
non cancer inflamed tissues, together with factors that are tumor
specific, including the presence of antigens able to elicit a chronic
stimulation of TIL. Thus, there is no tissue that would constitute
an obvious source of T cells to which TIL should be compared,
and PBT appear to be a fair reference.
A third issue concerns the quantitative importance of PD-1 in
contributing to the dysfunctional state of TIL, besides other,
distinct immunosuppressive factors and its mode of action. The
most common scheme is that PD-1 is an inhibitory receptor, able
to recruit the phosphatases SHP-1 and SHP-2 [15], just like other
inhibitory receptors such as KIR [16] expressed by NK and some
T cells. The alterations of TCR signalling resulting from the
presence of PD-1 are expected to resemble those resulting from the
co-clustering of activation and inhibitory receptors in NK cells,
leading to a blockade of the activation pathway. Even if such a
scheme sounds plausible, it is far from having been demonstrated
concerning the mode of action of PD-1 in human TIL. In
particular, it assumes that an inhibitory effect of PD-1 can only be
observed when it interacts with one of its ligands, PD-L1 or PD-
L2, a point that deserves discussion. Indeed, some receptors have
been shown to be active without engagement by their ligand [17].
Such a scheme should be tested by using early TCR signalling
readouts. Instead, most conclusions concerning the importance of
PD-1 in altering TIL functions have been based so far on late
responses such as TIL proliferation that integrates many signals in
addition to early TCR triggering. In addition, proliferation is
measured after several days in culture, i.e., in cells that have been
kept away from the tumor microenvironment. Even under these
conditions, although the importance of PD-1 has been repeatedly
stressed, and despite the existence of correlations between reduced
patient survival and expression of PD-1 ligand (PD-L1) in human
tumors [18,19], a whole series of data shows that the real
contribution to human TIL dysfunction could be quantitatively
quite modest [20]. Finally, the commonly admitted explanation
concerning the mode of action of PD-1 leads to the prediction that
upon inhibition of SHP-1 and SHP-2, one should observe an
improvement of early TCR signalling in TIL, which has never
been demonstrated.
It thus appears that there is an important lack of precision and
quantification in the common views concerning the characteriza-
tion of early signalling defects in fresh human TIL, and concerning
the relative contribution of PD-1 in TIL unresponsiveness. The
present work aims at re-evaluating these different issues.
Results
Early T cell signalling are altered in human TIL
The functional state of human TIL freshly isolated from three
types of tumors (non-small cell lung carcinoma (NSCLC),
melanoma and renal cell carcinoma (RCC)) has been investigated
within a few hours after tumor resection. Following TCR
stimulation, the activation of the Ca, Akt and ERK pathways
are required for a full activation [21]. Figure 1A shows that the Ca
response elicited by anti-CD3 stimulation in TIL was severely
depressed, on average ,7 times smaller in TIL compared with
peripheral blood T-cells (PBT). The phosphorylation of Akt
induced by CD3/CD28 cross-linking was also severely affected
(,15 times reduction compared to PBT, Fig. 1B) whereas levels of
phosphorylated ERK was only 2 to 3 times reduced in TIL after 2
minutes of anti-CD3-activation (Fig. 1C).
In addition, only a minority of TIL activated with anti-CD3/
anti-CD28-coated beads produced IFN-c (supplementary Fig. S1).
Of note, PMA/ionomycin-activated TIL produced large amounts
of IFN-c, suggesting that the majority of TIL were differentiated in
effector T cells capable of producing IFN-c if early TCR signalling
is bypassed.
Altogether, these data show that TIL have gone through a
process of differentiation into effector cells, but that TCR
signalling was blunted at an early level, affecting severely the
Ca- and Akt-pathways, and to a lesser extent, ERK activation.
These alterations led to a profound defect in the ability of TIL to
produce IFN-c in response to TCR stimulation.
Upon interaction with myeloid or tumor cells, TIL give
weak Ca responses
Next, we examined if the weak reactivity of TIL was also
observed upon interaction with freshly isolated tumor-derived cells
presenting antigens. Such interactions led to occasional Ca
responses of small amplitude (Fig. 2A). Even when pulsed with a
cocktail of superantigens (SAg), tumor-derived cells triggered
much smaller responses in TIL compared to PBT, indicating that
TIL are dysfunctional even under conditions where antigen is not
limiting. We then examined which cell type was the most likely to
be in contact with TIL within the tumor. Observations of
fluorescently labelled lung tumor slices indicate that TIL (CD3
+
cells) do interact in situ with monocytes/macrophages (CD14
+
cells) and are mostly present in the stromal zone (Fig. 2B) whereas
the striking paucity of TIL in the tumor mass (EpCAM
+) makes
frequent TIL-tumor cells interactions quite unlikely. These
important findings will be analyzed in detail in a distinct paper
(Salmon et al, in preparation).
TIL quickly recover part of their function after tumor
dissociation
After tumor dissociation, even though the different cell types
present in the tumor remain in the same culture dish, the influence of
the tumor microenvironment on the functional state of TIL may be
reduced by the destruction of the native 3D structure. To examine
the consequences of such an alteration of the microenvironment, we
monitored the functional state of TIL in the hours following tumor
dissociation. The ability of TIL to give a Ca response was markedly
increased within a few hours (already at 12 h, Fig. 3A) with a plateau
reached at 24 h and 36 h after dissociation of melanoma and lung
tumors, respectively (Fig. 3B). The recovery of TIL from RCC was
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PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17621slow but was conspicuous at 72 h (Fig. 3B). Note that the addition of
exogenous IL-2 in the culture did not improve the ability of TIL to
recover a Ca response to anti-CD3 stimulation (data not shown).This
differs from recovery of late effector TIL functions previously
observed that required the presence of IL-2 [9], Thus, the disruption
of the tumor microenvironment was sufficient to allow the recovery of
aC ar e s p o n s ei nT I L .
With lung tumors that allow the isolation of enough cells to
study conjugates, Ca responses elicited by interaction between TIL
and large cells could be observed (supplementary Movie S1) even
in the absence of added superantigen, albeit larger in its presence.
Under these conditions, we could detect a partial recovery of these
responses, the average responses at 24 h being 136% and 112% of
the responses ex vivo for conjugates formed with or without SAg,
respectively (n=3 tumors in each case).
The analysis of the functional recovery of TIL was further
assessed by looking at the phosphorylation of ERK and Akt, and
the ability to secrete IFN-c. For all these readouts, a partial but
significant recovery of TIL functions was observed after one to two
days in culture (Fig. 3C).
Altogether, these data show that the functional alteration of TIL are
reversible, at least in part, and that the severity with which the tumor
microenvironment elicits TIL anergy depends on the tumor type.
PD-1, but not its ligands, is frequently expressed in tumor
biopsies
As PD-1 expression on human TIL has been reported [22,23],
we examined how systematic this expression was, and to what
extent it could contribute to TIL anergy. We show on three tumor
Figure 1. Early T cell signalling is altered in human TIL. (A) Left, typical example of Ca mobilisation after anti-CD3 stimulation (arrow) in TIL
from a NSCLC biopsy, compared to PBT (In this and following figures, each Ca recording corresponds to the average of 10–30 cells). Right, mean Ca
measured in TIL (NSCLC n=23; melanoma n=4; RCC n=8) and PBT (n=5 healthy donors). (B) Examples (left) and mean percentage (right) of Akt
phosphorylation elicited by anti-CD3/anti-CD28 stimulation in TIL (n=7 tumors) and PBT (n=3 healthy donors). (C) Examples (left) and mean
percentage (right) of anti-CD3-induced ERK phosphorylation in TIL (n=12) and PBT (n=3). Data represent mean +/2 SEM; * p,0.05, ** p,0.01,
*** p,0.001 (Student t test).
doi:10.1371/journal.pone.0017621.g001
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and supplementary Fig. S2). In.90% of TIL from 50 tumors, the
MFI ratio of PD-1, relative to isotype labelling, was .2, and in
68% of them .5. Much lower levels were observed on PBT or on
T cells isolated from non-tumoral lung tissues or benign RCC.
The expression of the ligands of PD-1, PD-L1 and PD-L2, has
been examined on tumor cells (CD45
-) and myeloid cells (CD45
+
ssc
high cells) freshly isolated from tumor biopsies. The levels of PD-
L1 and PD-L2 were usually lower than those observed on
activated monocytes (supplementary Fig. S2). Depending on the
tumor type, PD-L1 was found to be expressed on tumor cells in
only 18 to 40% of the biopsies (Fig. 4B). It was expressed at similar
frequencies on myeloid cells infiltrating the tumors. PD-L2 was
preferentially expressed on myeloid cells and was rarely detected
on tumor cells. In rare cases (18% of tumor specimens), a very
weak expression of PD-L1 was detectable on lymphocytes (data
not shown) but it never reached the level observed on tumor or
myeloid cells. The expression of PD-L1 was also detected by
microscopy in some tumors but not others (Supplementary Fig.
S3).
Thus, PD-L1 or PD-L2 are not expressed by every tumor,
whereas a common feature between the different tumor types is
the expression of PD-1 on TIL. One may thus wonder if PD-1
expression could influence TIL reactivity in tumors independently
of engagement by its ligands.
PD-1 expression is associated with a chronic activation
and with the anergic state of TIL
Different approaches were used for assessing the functional
importance of PD-1 in human TIL anergy.
First, we observed that TIL tended to lose PD-1 expression in
culture, a roughly four-fold reduction being reached after 2 days
(Supplementary Fig. S4A).
TIL maintained a significantly higher expression of PD-1 when
cultured with anti-CD3 compared to non-stimulated TIL (p,0.05,
n=5, data not shown). In addition, PBT activated with anti-CD3/
anti-CD28-coated beads express PD-1 and this expression was
rapidly lost when the stimulation was interrupted, contrary to cells
for which stimulation was sustained (Supplementary Fig. S4B),
indicating that a continuous engagement of the TCR is necessary
for maintaining a high PD-1 expression on T cells. These
observations strongly suggest that TIL are chronically activated
in the tumor microenvironment. This conclusion is further
strengthened by the fact that 75% of TIL on average express
CD69 ex vivo (data not shown).
Next, we examined if there was a correlation between PD-1
expression and TIL reactivity ex vivo (Fig. 5A). Data were obtained
with TIL from NSCLC, with which the largest number of
experiments has been technically possible. At first glance, the anti-
CD3-induced Ca response does not appear correlated with PD-1
expression by TIL. However, the largest Ca responses were never
observed when TIL strongly expressed PD-1. A cluster of TIL
shows a small Ca response despite the absence of strong PD-1
expression. Such a group may reveal that other inhibitory factors
such as TGF-b and Galectin-3 play a key role in anergizing these
TIL even when PD-1 is low [12,24]. Interestingly, 4 out of the 6
tumors in the cluster with low PD-1 expression and Ca responses
(white circles in Fig. 5A), showed a marked necrosis, an
observation that might be related with the fact that TGF-b
dependent healing mechanisms are triggered by cell death [25].
To further examine a possible link between PD-1 expression
and TIL unresponsiveness, we looked at IFN-c secretion by TIL.
It clearly appeared that the few TIL able of producing IFN-c ex
vivo were PD-1
neg/low, compared to PD-1
high TIL that do not
produce any IFN-c (Fig. 5B).
Altogether, these data indicate that the ability of fresh human
TIL to respond to TCR stimulation is favoured by the low
expression of PD-1.
Sodium stibogluconate attenuates inhibitory signals in
TIL, and in PBT overexpressing PD-1
The intracellular part of PD-1 is able to recruit SHP-1 and
SHP-2 after pervanadate treatment of T-cells, and a role of these
phosphatases in PD-1 inhibitory signalling has been proposed
[15]. When TIL were treated for 20 min with sodium stiboglu-
conate (SSG), an inhibitor of SHP-1 and SHP-2 [26], the anti-
CD3-induced Ca response of these cells was markedly increased,
more than 3-fold on average (Fig. 6A and B). In addition, SSG-
treated TIL tended to show larger Ca responses in conjugates with
large cells freshly isolated from NSCLC as compared to untreated
Figure 2. Interactions between TIL and large cells present in
the tumor. (A) Average Ca responses triggered in TIL by interaction
(arrow) with large cells either unloaded (thin line, average from 7 NSCLC
tumors) or loaded with SAg (thick line, n=6 NSCLC tumors) and in PBT
(open symbols, n=15 cells). (B) A typical triple labelling in a NSCLC
slice, of TIL (CD3
+ in red), monocytic (CD14
+ cells in green) and tumor
cells (EpCAM
+ in blue). Zoom: arrows point to three CD3
+-CD14
+
conjugates.
doi:10.1371/journal.pone.0017621.g002
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reverse the phosphorylation of ERK and Akt but we did not
observe recovery for these pathways after a short treatment of TIL
with the inhibitor (data not shown).
In all experiments performed with anti-CD3 stimulation, there
was no concomitant engagement of PD-1 with its ligands,
susceptible of providing an inhibitory signal. Is it conceivable that
nevertheless, in such experiments, the mere expression of PD-1
was sufficient to deliver an inhibitory signal to T cells? To test this
hypothesis, PBT were transfected with a full length human PD-1-
YFP construct. In PD-1
+ transfected-PBT, the anti-CD3-induced
ERK response represented 74 +/2 7.5% (mean+/-SEM, n=5) of
that of YFP
+ PBT. The anti-CD3-induced Ca response was also
reduced and was 70+/29.4% (n=7) of that of YFP
+ PBT
(Fig. 6C). In addition, we could demonstrate that the inhibition of
the Ca response (but not the ERK one), was fully reversed when
PD-1
+ PBT were treated with SSG (Fig. 6 C and D). Of interest,
SSG had no effect on the anti-CD3-induced Ca response in
control PBT (Fig. 6D). Thus, the mere expression of PD-1 is
sufficient to partially inhibit anti-CD3-induced Ca and ERK
responses, but only the inhibition of the Ca response appears to
involve SSG-sensitive phosphatases.
Discussion
In the present paper, we have characterized for the first time
three signalling pathways that are simultaneously affected in
human TIL, participating to their anergy. PD-1 expression
contributes only to a fraction of this anergy. Unexpectedly, an
inhibitory effect of PD-1 may be exerted even in the absence of its
ligands. Finally, by using SSG, an inhibitor of SHP-1 and SHP-2,
we show that these phosphatases contribute to the anergic state of
TIL and to the ligand-independent inhibitory effect of PD-1.
Our data underline the importance of testing the functionality
of TIL right after tumor resection, as the functional state of TIL
monitored 12 h later is already different from that of freshly
isolated TIL and thus, from TIL in vivo. In previous reports, the
anergy of TIL was reversed by addition of IL-2 in culture [9]
which was consistent with the view that experimental, ionomycin-
induced anergy, could be reverted by adding exogenous IL-2. We
have shown for the first time that a recovery of the Ca response of
TIL may be observed a few hours after disrupting the tumor
microenvironment, without the need to be supplemented with
exogeneous IL-2.
By analyzing different pathways (Ca, Akt and ERK), we have
identified several features of human TIL anergy. Our data show
that this state differs from the existing murine models of anergy, in
particular from a state extensively studied after treating T cells for
16 h with ionomycin [27], or after in vitro stimulation of the TCR
without costimulation, a protocol called "signal 1 without signal
2". Indeed, experimental ionomycin-induced anergy affects
preferentially the ERK pathway, whereas in real human TIL
anergy, ERK is the least affected pathway. Human TIL anergy is
more similar to the state of adaptive tolerance [28] triggered in
murine models by chronic stimulation, and in which the Ca
pathway is more severely affected than the ERK one. However,
chronically stimulated murine "adapted" T cells do not express
CD69, and express a modest level of PD-L1 [29], contrary to
human TIL, that express CD69 but not PD-L1 (our data). Another
difference between TIL and chronically stimulated murine
"adapted" T cells is that TIL are usually in an inflammatory
environment, including cytokines such as TGF-b, which is not
necessarily the case in experimental models of chronic T cell
stimulation.
PD-1 is a marker of recently activated T cells, which could be
exhausted in some cases [1] and quite functional in other cases
Figure 3. TIL show a spontaneous functional recovery in culture. (A) Typical average Ca responses in ex vivo NSCLC TIL and after 12 h in
culture (n=20–24 cells). (B) Average kinetics of Ca recovery in TIL from melanoma (n=7), NSCLC (n=23) and RCC (n=7). (C) Percentage of
phosphorylated ERK (left, n=13), phosphorylated Akt (middle, n=7) and IFN-c producing TIL (right, n=3), at day 0 and after 24–48 h in culture. Data
represent mean +/2 S E M;*p ,0.05, ** p,0.01, *** p,0.001 (Student t test).
doi:10.1371/journal.pone.0017621.g003
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their expression of both CD69 and PD-1 and by the fact that PD-1
expression is maintained on TIL kept in vitro in the presence of
anti-CD3 Ab, and decreases when the TCR signal is stopped.
Although it is commonly considered that intratumoral TIL
activation results from interactions with tumor cells, our data
show that chronic TIL activation is more likely to result from
interactions with cells present in the tumor stroma (in particular
myeloid cells), because this is where TIL are mostly present. These
chronically activated cells are experienced T cells, a conclusion
that fits with our observation that they secrete cytokines in
response to PMA/ionomycin, consistently with some reports [8,9]
but not all [10,11]. Like memory cells, they have a lower CD28
expression than naı ¨ve T cells, which might make them less
sensitive to anti-CD3/anti-CD28 stimulation than naı ¨ve T cells.
Our data show that PD-1 is not only a marker of TIL, it is also
one of the factors that actively contribute to their anergy. This
conclusion has already been proposed in several studies in which T
cells were cultured for a week or so with anti-PDL1 antibodies
[31,32]. However, what was really tested in these studies was the
ability of PD-1 to partially inhibit cell proliferation and associated
cytokine production during in vitro recovery from anergy. For the
first time, we have tested the functional state of ex vivo TIL with
several readouts (Ca, phosphorylation of ERK and Akt) quite
upstream TCR signalling, with no interference from the recovery
phase. The responsiveness of these ex vivo TIL was shown to be
favoured by the low expression of PD-1 (Fig. 5), although PD-1
was obviously not the only anergy-inducing molecule. The
conclusion that PD-1 could interfere with TCR signalling was
further strengthened by our observation that in PBT transfected
with PD-1, a limited but significant inhibition of TCR signalling
was observed. The possibility of an inhibitory effect of PD-1 even
in the absence of ligand is of conceptual importance, as PD-1
ligands were not observed in all tumors. We propose that even in
such tumors, PD-1 may still exert a partial inhibitory effect.
We have also shown that the Ca response of ex vivo TIL could be
potentiated by SSG, an inhibitor of SHP-1 and SHP-2. This shows
that an inhibitory signalling associated with these phosphatases
contributes to TIL anergy. Such an effect does not allow
distinguishing if these phosphatases are associated with PD-1 or
with other inhibitory receptors. However, we have also shown that
the inhibitory effect exerted by PD-1 in PD-1-transfected PBT was
reversed by SSG, underlining the potential importance of the PD-
1/SHP-1/SHP-2 pathway. This finding is of importance, given
that SSG has already been successfully used to treat patients for
another disease, leishmaniasis [33].
In conclusion, we have shown that several causes contribute to
the weak antitumoral efficiency of TIL. First, as will be studied in
more details in another study, their preferential location in the
stroma rather than in contact with tumor cells does not favour an
anti-tumor cytotoxic action. Second, TIL are in an anergic state
that profoundly affects several signalling pathways, when analyzed
immediately in ex vivo TIL, but which starts to reverse rapidly
when the cells are put in culture. The systematic presence of PD-1
at the TIL surface is both a witness of their chronic activation in
the tumor stroma, and one amongst several anergizing factors.
The fact that a 20–30% inhibition of the anti-CD3-induced Ca
response and ERK phosphorylations are observed in PBT
transfected with PD-1 shows that PD-1 may exert an inhibitory
effect even without interacting with its ligands. The observation
that the Ca response of ex vivo TIL is more severely affected than
that of PD-1-transfected PBT underlines that other causes concur
to maintain anergy in TIL affected by a set of inhibitory
mechanisms [12,20,24,34]. The presence of two of them,
membrane-associated TGF-b and Galectin-3 can be reduced by
a short exposure of TIL to acidic pH ([12]; P. Van der Bruggen,
personal communication). In our hands, such a treatment could
indeed partially restore Ca response in fresh TIL (data not shown)
without affecting PD-1 expression. This shows that even if TIL
anergy cannot be only related to and correlated with PD-1
expression, PD-1 is one amongst several factors that all contribute
to a fraction of TIL anergy. This study should help clarifying one
of the aspects of the multifactorial phenomenon of human TIL
anergy, which we hope to be able to reverse in the future.
Materials and Methods
Human Tumors and Ethics Statement
Fresh tumors were obtained with written informed consent prior
to inclusion. Samples from patients with RCC (n=18) and
NSCLC (n=40) were obtained from surgical therapeutic excision.
Pathological examination of RCC tumors identified clear cell
carcinoma (72%) and papillary carcinoma (28%). Four patients
who were operated for benign renal tumors were also included as
controls. NSCLC specimens were from adenocarcinoma (40%),
large cell carcinoma (15%), squamous cell carcinoma (18%), and
Figure 4. PD-1, but not its ligands, is frequently expressed in
tumor biopsies. (A) PD-1 expression on PBT, melanoma, Lung
specimens (control or tumoral) and RCC (benign and tumoral). PD-1
level is expressed as a ratio relative to the MFI of the control isotype.
Bars correspond to the Median; * p,0.05, ** p,0.01, *** p,0.001
(Mann Whitney). (B) Percentage of tumor biopsies showing positivity
for PD-L1 or PD-L2 staining (Melanoma n=15; NSCLC n=15; RCC
n=12).
doi:10.1371/journal.pone.0017621.g004
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collected from the surgical specimen at a distance from the
primary NSCLC or from a different lesion-free lobe as tissue
reference. Melanoma samples (n=18) were collected from
cutaneous metastasis who were removed for a pathological
examination. The study protocol was approved by the CPP Ile
de France ethical committee and was performed according to the
Declaration of Helsinki Principles.
Cell Isolation
Fresh biopsies were dissociated immediately after tumor
resection. Single cell suspensions were prepared by mechanical
dissociation followed by incubation in a non enzymatic solution
(BD Cell recovery solution, BD Biosciences) for NSCLC (1 h at
+4uC) or with collagenase D and DNAse enzymes (Roche) in
RPMI without serum for cutaneous melanoma and RCC (30 min
at 37uC). Cell suspensions were then filtered (100 mm) to remove
membrane aggregates, rinsed twice with PBS 5% FCS 0.5 mM
EDTA. TIL suspensions were enriched by Ficoll centrifugation
(Ficoll-Paque Plus, Amersham Biosciences). For experiments with
conjugates, TIL and large cells were separated on a Ficoll
gradient. TIL were either used immediately or let to recover in
short term culture at 2.10
5 cells/200 ml in 96 U bottom well plates.
IL-2 (10 U/ml) was added when TIL were used in cytokines
Figure 5. PD-1 contributes to the anergic state of TIL. (A) Ca responses and PD-1 levels measured on ex vivo TIL from 16 NSCLC. Open circles
correspond to necrotic tumors. Linear regression curve is shown (r
2=0.034). (B) Production of IFN-c by TIL stimulated or not (NS) with anti-CD3/anti-
CD28 coated beads. Left, typical dot plot from a NSCLC biopsy. Right, average (n=3 tumors). Data represent mean +/2 SEM; * p,0.05, ** p,0.01,
*** p,0.001 (Student t test).
doi:10.1371/journal.pone.0017621.g005
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healthy donors (Etablissement Franc ¸ais du Sang, Paris) were
isolated by Ficoll gradient followed by negative selection using a T
cell isolation kit (BD Biosciences).
PBT transfection with pEYFP-N1-PD1 construct
A full length human PD-1 cDNA (kindly provided by D. Olive,
Marseille, France) was subcloned into pEYFP-N1 vector. PBT
were nucleofected with PD-1 YFP or empty YFP vector (Amaxa),
according to the manufacturer’s instructions, and were used 18 h
after transfection.
Phenotyping by flow cytometry
Antibodies used for phenotyping PD-1 and its ligands (anti-
CD3-PerCP, anti-PD1-PE, anti-CD45-FITC, anti-CD3-PerCP,
anti-PDL1-PE, anti-PDL2-APC, anti-CD8-FITC, anti-CD4-APC,
anti-CD69-PE Ab, IgG1-APC, IgG1-PE) were all from BD
Pharmingen. Positive staining for PD-1, PD-L1 and PD-L2 were
determined by comparing the MFI with specific mAb compared to
the MFI with the respective control isotype. Cell suspensions were
incubated for 30 min at +4uC with Ab, washed twice in PBS and
fixed in PFA 1%. Cells were acquired on a FACSCalibur (BD) and
analysed with FlowJo flow cytometry analysis Software.
ERK and Akt phosphorylation
For ERK phosphorylation, washed TIL or PBT were stimulated
with anti-CD3 Ab (10 mg/ml, UCHT1, BD Pharmingen) for
2 min at 37uC. For Akt phosphorylation, cells were coated with
mouse anti-CD3 and mouse anti-CD28 (10 mg/ml, BD Pharmin-
gen) Ab on ice for 20 min, followed by crosslinking with an anti-
mouse IgG for 10 min at 37uC. After fixation with 4% PFA and
permeabilisation with 0.1% saponin, cells were stained with
purified mouse anti-human phosphorylated Akt (Cell signalling),
phosphorylated ERK (Cell signalling) Ab and then with biotin
conjugated donkey anti-mouse IgG Ab (Jackson ImmunoResearch
Laboratories, INC.) and finally with streptavidin PE (BD Pharm).
After washing, cells were acquired by FACSCalibur or fixed with
1% PFA and stored at +4uC until use.
Calcium measurements
For imaging experiments, Ca responses were measured as
previously described [35]. Briefly, T cells (PBT or TIL) were
loaded with 0.5 mM Fura-2/AM (Molecular Probes) for 15 min at
37uC in mammalian saline. T cells were stimulated with 10 mg/ml
anti-CD3 (UCHT1) or were added to tumor-derived large cells,
pulsed or not with a cocktail of superantigens (SEA, SEB and SEE
at 200 ng/ml, Toxin Technology). In some experiments, T cells
were treated with sodium stibogluconate (SSG, 50 mg/ml,
Calbiochem) during fura-2 loading, washed and maintained in
medium containing SSG for the assay.
Image were acquired at 37uC every 5 s on a Nikon microscope
(TE300 or TE2000), with a 10x or 20x objective. Cells were
excited alternatively at 350 nm and 380 nm and emissions at
510 nm were used to measure Ca variations with Metafluor
software (Molecular devices). In experiments with YFP-transfected
PBT, YFP fluorescence was measured every 10 s in parallel to Ca.
Ca levels are represented as a ratio 350/380 fluorescence intensity
normalized to the ratio at t0.
For Ca measurements by flow cytometry, T cells were loaded
with 1.5 mM Indo-1 for 30 min at 37uC, washed and rested for 10
before Ca measurements performed on a LSR2 (BD), the tube
being maintained at 37uC during acquisition (360 nm excitation,
420 and 530 nm emission). The Ca baseline level was measured
for 2 min before stimulation with anti-CD3 (UCHT1, 10 mg/ml).
Intracellular cytokine staining
Cell suspensions (4.10
5 cells/well) were incubated in 96 well U
bottom plate with anti-CD3/anti-CD28 coated beads (1 bead for 5
cells, Dynal) or PMA (25 ng/ml) and Ionomycin (5 mg/ml) in the
presence of Brefeldin A (2 mg/ml, Sigma). After overnight
incubation, cells were washed in PBS 2% FCS and stained for
detection of cell surface markers and intracellular cytokines with
the IntraStain kit (BD) as recommended by the manufacturer.
Cells were stained with anti-CD3-PerCP for 15 min at room
temperature, fixed, permeabilized, and stained with anti- IFN-c-
APC Ab (BD Pharmingen) for 30 min at room temperature. After
washing, cells were fixed with PFA 1% and stored at +4uC until
acquisition.
Figure 6. PD-1 expression delivers an inhibitory signal
attenuated by sodium stibogluconate. (A) Typical average Ca
responses elicited by anti-CD3 (arrow) in melanoma TIL, treated or not
for 20 min with SSG. (B) Average Ca responses in TIL treated or not with
SSG (n=12 tumors). (C) Top: fluorescence images of PD-1 and YFP-
transfected PBT. Bottom: typical average Ca responses triggered by
anti-CD3 (arrows) in YFP
+ and PD-1
+ transfectants (left) and in PD1
+
transfectants treated or not with SSG (right). (D) Average Ca response
(in % of the response in YFP
+ cells) in YFP
+ and PD-1
+ transfectants
treated or not with SSG (n=7 independent experiments). Data
represent mean +/2 SEM * p,0.05, ** p,0.01, *** p,0.001 (Student
t test).
doi:10.1371/journal.pone.0017621.g006
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Immunofluorescence on tumor slices was performed as
described previously [36]. Briefly, small tumor pieces were
embedded in 5% low-gelling-temperature agarose (type VII-1;
Sigma-Aldrich). Slices (400 mm) were cut with a vibratome (VT
1000S; Leica) and fixed for 20 min with 2% PFA at room
temperature. Immunostaining were performed at 4uC for 2 h or
overnight with primary mAb specific for CD3 (IgG1, UCHT1),
CD14 (IgG2a, BD Pharmingen) and biotinylated anti-EpCAM
mAb (R&D System). Immunodetection was performed using Goat
anti-IgG1 Alexa Fluor 647 and Goat anti-IgG2a Alexa Fluor 488
(Invitrogen) and Streptavidin-PE (BD Pharmingen), respectively.
Antibodies (200 ng/slice) were diluted in PBS, 0,5% BSA, 2% AB
serum. Images were obtained with an inverted microscope
(TE2000-E; Nikon) equipped with a 20x and a 60x objective,
and MetaVue imaging software.
Cytokeratin/PD-L1 double staining of NSCLC frozen
sections
Frozen pulmonary tissues were sectioned at 4–6 mm with a
cryostat, placed on slides, air dried and fixed for 10 min with
100% acetone. Frozen tissues were stained with rabbit anti-human
cytokeratin (Novocastra, Newcastle upon Tyne UK) and goat anti-
human PD-L1 (R&D, Minneapolis, USA), followed donkey anti-
rabbit biotinylated (Jackson Immunoresearch, West Grove, PA,
USA) and FITC donkey anti-goat (Jackson Immunoresearch, West
Grove, PA, USA) followed by cyanine 3-conjugated streptavidin
(Amersham Biosciences, Uppsala, Sweden). Fluorescent images of
mounted sections were analyzed with an epifluorescent micro-
scope DMR (Leica Microsystems, Wetzlar, Germany).
Supporting Information
Figure S1 Intracellular IFN-c detection in NSCLC TIL
stimulated or not (NS) with anti-CD3/anti-CD28 coated beads
or with PMA/ionomycin. Left, typical dot plots. Right, average
percentage of IFN-c
+ T cells (n=3 NSCLC).
(TIF)
Figure S2 (A) Typical examples of PD-1 expression profiles on
TIL from two different tumors (Tum1 and Tum2). (B) Example of
PD-L1 and PD-L2 expression on CD45
- (tumor) cells and CD45
+
ssc high (myeloid) cells from a fresh NSCLC biopsy, and on IFN-c
activated monocytes.
(TIF)
Figure S3 PD-L1 expression in situ. Top: example of NSCLC
with PD-L1 expression; bottom: example of a negative tumor.
(TIF)
Figure S4 (A) Decrease of PD-1 expression in culture. PD-1
expression (MFI ratio) on TIL decreases in culture with time (n=4
to 9 biopsies). Data represent mean +/2 SEM. (B) PD-1
expression on day 6-activated T-cells decreases more rapidly in
culture when TCR stimulation is stopped (no bead) compared to
chronically activated T-cells (beads). Data represent mean +/2
SEM from 3 independent experiments.
(TIF)
Figure S5 Ca response in SSG-treated TIL conjugated
with large cells from tumors. Mean Ca responses measured
in TIL treated (thick line, n=3 NSCLC tumors) or not (thin line,
n=7 NSCLC) with SSG. Responses were triggered by the contact
(arrow) with large cells isolated from the same tumors.
(TIF)
Movie S1 Ca response in TIL interacting with a large
cell isolated from a NSCLC tumor. After 3 days in culture,
fura-loaded TIL were added to large cells isolated from the
autologous NSCLC tumor. Ca mobilisation in TIL was monitored
under microscope as described in the Methods section. Both cell
types are visible in the brightfield image (top); in the Ca movie
(bottom), one can see that the TIL makes several Ca transients.
(AVI)
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